NGL Fine Chem reported a strong June quarter with revenue up 33.57% to ₹139.16 crore and profit nearly doubling to ₹18.40 crore year-on-year. The results were approved by the board and have an unmodified auditor opinion.
NGL Fine Chem Reports Stellar Q1 FY27 Results
Consolidated revenue from operations ₹139.16 crore; Profit for the period ₹18.40 crore.
Reader Takeaway: Robust YoY growth in revenue and profit driven by operational efficiency and consistent demand in its pharmaceutical segment.
What just happened
NGL Fine Chem announced its financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue from operations of ₹139.16 crore, a significant increase of 33.57% compared to ₹104.19 crore in the same quarter last year.
Profit for the period also saw substantial growth, rising by 99.13% to ₹18.40 crore from ₹9.24 crore in the corresponding quarter of the previous year. Basic earnings per share (EPS) stood at Rs 29.78.
Why this matters
These strong results indicate NGL Fine Chem's continued positive trajectory in the pharmaceutical manufacturing sector. The substantial year-on-year growth in both revenue and profit signals healthy demand for its products and effective operational management.
The backstory
NGL Fine Chem operates as a single business segment focused on pharmaceutical manufacturing. The company has consistently aimed for growth and efficiency within this core area.
What changes now
The strong performance in the June 2026 quarter reinforces the company's growth momentum. Investors will be looking for sustained profitability and operational expansion in upcoming financial periods.
Risks to watch
While the results are positive, investors should monitor the company's ability to maintain current margins and growth rates amidst potential market fluctuations and competitive pressures within the pharmaceutical industry.
Peer comparison
NGL Fine Chem operates within the pharmaceutical manufacturing segment. Specific peer comparisons were not detailed in the filing, but the reported growth rates suggest competitive performance.
Context metrics (time-bound)
Consolidated revenue for the quarter ended June 30, 2026, was ₹139.16 crore, up from ₹104.19 crore for the quarter ended June 30, 2025 (+33.57%).
Consolidated profit for the quarter ended June 30, 2026, was ₹18.40 crore, up from ₹9.24 crore for the quarter ended June 30, 2025 (+99.13%).
What to track next
Investors should closely track NGL Fine Chem's future quarterly results, focusing on revenue growth, profitability margins, and any new developments within its pharmaceutical manufacturing operations.